Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Axsome Therapeutics, Inc. (AXSM : NSDQ)

• Company Description    Axsome Therapeutics is a biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS), disorders for which there are limited treatment options available. Number of Employees: 925

• Price / Volume Information    Yesterday's Closing Price: $235.97 Daily Weekly Monthly 20 Day Moving Average: 920,490 shares Shares Outstanding: 51.46 (millions) Market Capitalization: $12,143.02 (millions) Beta: 0.59 52 Week High: $236.84 52 Week Low: $96.09 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 29.14% 22.83% 12 Week 44.60% 33.67% Year To Date 29.20% 17.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL One World Trade Center 22nd Floor - NEW YORK,NY 10007 USA ph: 212-332-3241 fax: 212-320-0245 None http://www.axsome.com

• General Corporate Information    Officers Herriot Tabuteau - Chief Executive Officer and Chairman Nick Pizzie - Chief Financial Officer Roger Jeffs - Director Mark Coleman - Director Mark Saad - Director Peer Information Axsome Therapeutics, Inc. (CORR.) Axsome Therapeutics, Inc. (RSPI) Axsome Therapeutics, Inc. (CGXP) Axsome Therapeutics, Inc. (BGEN) Axsome Therapeutics, Inc. (GTBP) Axsome Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 05464T104 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/03/26 Share - Related Items Shares Outstanding: 51.46 Most Recent Split Date: (:1) Beta: 0.59 Market Capitalization: $12,143.02 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.81 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.14 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 11.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/03/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 222.45 Price/Cash Flow: - Price / Sales: 17.15 EPS Growth vs. Year Ago Period: -57.50% vs. Previous Quarter: -77.46% Sales Growth vs. Year Ago Period: 57.42% vs. Previous Quarter: -2.45% ROE 03/31/26 - -267.16 12/31/25 - -232.61 09/30/25 - -277.31 ROA 03/31/26 - -28.53 12/31/25 - -25.84 09/30/25 - -28.81 Current Ratio 03/31/26 - 1.39 12/31/25 - 1.55 09/30/25 - 1.57 Quick Ratio 03/31/26 - 1.32 12/31/25 - 1.48 09/30/25 - 1.50 Operating Margin 03/31/26 - -27.32 12/31/25 - -26.26 09/30/25 - -31.75 Net Margin 03/31/26 - -26.59 12/31/25 - -28.69 09/30/25 - -40.90 Pre-Tax Margin 03/31/26 - -26.66 12/31/25 - -28.77 09/30/25 - -41.05 Book Value 03/31/26 - 1.06 12/31/25 - 1.75 09/30/25 - 1.46 Inventory Turnover 03/31/26 - 2.06 12/31/25 - 2.20 09/30/25 - 2.46 Debt-to-Equity 03/31/26 - 2.27 12/31/25 - 1.38 09/30/25 - 1.66 Debt-to-Capital 03/31/26 - 69.38 12/31/25 - 58.00 09/30/25 - 62.39

Powered by Zacks Investment Research ©